Company Architecture
Two complementary corporate entities under the BioScience Americas, LLC umbrella — BioX Companies (the healthcare services operating company) and BioX Innovations Vault (the IP and biotech platform) — each engineered for a distinct purpose, with BioXcellerator operating as the flagship clinical brand under BioX Companies.
BioX Companies
BioX Companies is the healthcare services operating company. BioXcellerator is the flagship clinical brand operating under BioX Companies — delivering regenerative medicine therapies to patients, generating current revenue, proving product-market fit, and capturing real-world outcomes data across 170+ conditions.
The world's most advanced regenerative medicine clinic. GCP-compliant, multi-ISO certified. 50,000+ stem cell applications across orthopedics, neurology, autoimmune, and aesthetics.
Premium longevity and wellness centers extending the BioXcellerator brand into the global longevity market.
Medical tourism accommodation integrated with the flagship clinic. Captures the full patient stay economics and extends the BioXcellerator experience.
U.S. proof engine enabled by Utah SB 199. First domestic delivery point for placental stem cell therapies under a licensed provider framework.
Multi-channel patient acquisition including direct-to-consumer, U.S. healthcare provider referral relationships, and international medical tourism networks.
Systematic real-world evidence collection across all treatment protocols — feeding back into BioX Innovations Vault R&D to continuously refine products.
BioX Innovations Vault, Inc.
BioX Innovations Vault, Inc. is the technology and intellectual property entity that creates, refines, protects, and scales the proprietary biologic products that BioX Companies delivers. It houses the manufacturing infrastructure, IP portfolio, and R&D capability driving long-term enterprise value.
Proprietary Wharton's Jelly MSC platform. The cornerstone cell therapy product with broad clinical application across multiple conditions and specialties.
Next-generation combination product pairing Wharton's Jelly MSCs with exosomes for enhanced therapeutic effect and broader clinical indication.
Standalone exosome product positioned in the rapidly growing exosome therapeutics market. Active U.S. healthcare provider relationships.
Secretome-based product representing the leading edge of cell-free regenerative medicine — the next frontier after exosomes.
In-house manufacturing facility with multiple ISO certifications and Good Clinical Practices compliance — full quality control from donor sourcing through final product release.
Growing portfolio of IP assets including trademarks, proprietary processes, protocols, and product formulations. Details available in the investor data room.
The Value Flywheel
Brands & Trademarks Architecture
Click any brand card to view a full product description, strategic purpose, and key investment highlights.